These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 35129002)

  • 1. Immune Checkpoint Inhibitors and Palliative Care at the End of Life: An Irish Multicentre Retrospective Study.
    O'Sullivan HM; Conroy M; Power DG; Bambury RM; O'Mahony D; Collins DC; O'Leary MJ; O'Reilly S
    J Palliat Care; 2022 Feb; ():8258597221078391. PubMed ID: 35129002
    [No Abstract]   [Full Text] [Related]  

  • 2. Duration of palliative care involvement and immunotherapy treatment near the end of life among patients with cancer who died in-hospital.
    Auclair J; Sanchez S; Chrusciel J; Hannetel L; Frasca M; Economos G; Habert-Dantigny R; Bruera E; Burucoa B; Ecarnot F; Colombet I; Barbaret C
    Support Care Cancer; 2022 Jun; 30(6):4997-5006. PubMed ID: 35192058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance status and end-of-life care among adults with non-small cell lung cancer receiving immune checkpoint inhibitors.
    Petrillo LA; El-Jawahri A; Nipp RD; Lichtenstein MRL; Durbin SM; Reynolds KL; Greer JA; Temel JS; Gainor JF
    Cancer; 2020 May; 126(10):2288-2295. PubMed ID: 32142165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Checkpoint Inhibitor Use Near the End of Life: A Single-Center Retrospective Study.
    Glisch C; Saeidzadeh S; Snyders T; Gilbertson-White S; Hagiwara Y; Lyckholm L
    J Palliat Med; 2020 Jul; 23(7):977-979. PubMed ID: 31702481
    [No Abstract]   [Full Text] [Related]  

  • 5. Initial Experience after Transition to Immune Checkpoint Inhibitors in Patients with Non-small Cell Lung Cancer Treated in a Rural Healthcare Region.
    Nieder C; Reigstad A; Carlsen EA; Flatøy L; Tollåli T
    Cureus; 2020 Feb; 12(2):e7030. PubMed ID: 32211263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Timing of palliative care referral and aggressive cancer care toward the end-of-life in pancreatic cancer: a retrospective, single-center observational study.
    Michael N; Beale G; O'Callaghan C; Melia A; DeSilva W; Costa D; Kissane D; Shapiro J; Hiscock R
    BMC Palliat Care; 2019 Jan; 18(1):13. PubMed ID: 30691417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy during the last 30 days of life and the role of palliative care referral, a single center experience.
    Woldie I; Elfiki T; Kulkarni S; Springer C; McArthur E; Freeman N
    BMC Palliat Care; 2022 Feb; 21(1):20. PubMed ID: 35125092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palliative care referral patterns and measures of aggressive care at the end of life in patients with cervical cancer.
    Bercow AS; Nitecki R; Haber H; Gockley AA; Hinchcliff E; James K; Melamed A; Diver E; Kamdar MM; Feldman S; Growdon WB
    Int J Gynecol Cancer; 2021 Jan; 31(1):66-72. PubMed ID: 33046575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of palliative care decisions making on hospital service use at end-of-life in patients with malignant brain tumors: a retrospective study.
    Nåhls NS; Leskelä RL; Saarto T; Hirvonen O; Anttonen A
    BMC Palliat Care; 2023 Apr; 22(1):39. PubMed ID: 37032344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Administration of Immune Checkpoint Inhibitors Near the End of Life.
    Bloom MD; Saker H; Glisch C; Ramnaraign B; George TJ; Markham MJ; Kelkar AH
    JCO Oncol Pract; 2022 Jun; 18(6):e849-e856. PubMed ID: 35254868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. When does early palliative care influence aggressive care at the end of life?
    Davis MP; Vanenkevort EA; Elder A; Young A; Ordonez IDC; Wojtowicz MJ; Ellison H; Fernandez C; Mehta Z; Behm B; Digwood G; Panikkar R
    Support Care Cancer; 2022 Jun; 30(6):5371-5379. PubMed ID: 35290511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early referral to a palliative team improves end-of-life care among gynecological cancer patients: a retrospective, population-based study.
    Paulsen T; Liland H; Myklebust TÅ; Lindemann K
    Int J Gynecol Cancer; 2022 Feb; 32(2):181-188. PubMed ID: 34987096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Findings on Chest CT Performed in the Emergency Department in Patients Receiving Immune Checkpoint Inhibitor Therapy: Single-Institution 8-Year Experience in 136 Patients.
    Smith DA; Radzinsky E; Tirumani SH; Guler E; Petraszko A; Kikano E; Hoimes CJ; Ramaiya NH
    AJR Am J Roentgenol; 2021 Sep; 217(3):613-622. PubMed ID: 33295801
    [No Abstract]   [Full Text] [Related]  

  • 15. Team-Based Hospice Referrals: A Potential Quality Metric for Lung Cancer in the Immunotherapy Era.
    Lycan TW; Buckenheimer A; Ruiz J; Russell G; Dothard AS; Ahmed T; Grant S; Grey C; Petty WJ
    Am J Hosp Palliat Care; 2023 Jan; 40(1):10-17. PubMed ID: 35512681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impacts of multidisciplinary meeting case discussion on palliative care referral and end-of-life care in lung cancer: a retrospective observational study.
    Sridharan K; Paul E; Stirling RG; Li C
    Intern Med J; 2021 Sep; 51(9):1450-1456. PubMed ID: 33463032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilization of Systemic Therapy in Patients With Cancer Near the End of Life in the Pre- Versus Postimmune Checkpoint Inhibitor Eras.
    Khaki AR; Chennupati S; Fedorenko C; Li L; Sun Q; Grivas P; Ramsey SD; Schwartz SM; Shankaran V
    JCO Oncol Pract; 2021 Nov; 17(11):e1728-e1737. PubMed ID: 34010026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palliative medicine favourably influences end-of-life cancer care intensity: a large retrospective database study.
    Chiaruttini MV; Corli O; Pizzuto M; Nobili A; Fortini G; Fortino I; Leoni O; Bosetti C
    BMJ Support Palliat Care; 2022 Dec; ():. PubMed ID: 36522144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Checkpoint Inhibitor Use Near the End of Life Is Associated With Poor Performance Status, Lower Hospice Enrollment, and Dying in the Hospital.
    Glisch C; Hagiwara Y; Gilbertson-White S; Gao Y; Lyckholm L
    Am J Hosp Palliat Care; 2020 Mar; 37(3):179-184. PubMed ID: 31307205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duration of palliative care involvement and cancer care aggressiveness near the end of life.
    Monier PA; Chrusciel J; Ecarnot F; Bruera E; Sanchez S; Barbaret C
    BMJ Support Palliat Care; 2020 Dec; ():. PubMed ID: 33355165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.